CN115088822A - 一种用于辅助治疗代偿期乙肝后肝硬化的蔬果昔及制作方法 - Google Patents
一种用于辅助治疗代偿期乙肝后肝硬化的蔬果昔及制作方法 Download PDFInfo
- Publication number
- CN115088822A CN115088822A CN202210622759.8A CN202210622759A CN115088822A CN 115088822 A CN115088822 A CN 115088822A CN 202210622759 A CN202210622759 A CN 202210622759A CN 115088822 A CN115088822 A CN 115088822A
- Authority
- CN
- China
- Prior art keywords
- vegetable
- fruit
- hepatitis
- cirrhosis
- post
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000019425 cirrhosis of liver Diseases 0.000 title claims abstract description 47
- 206010016654 Fibrosis Diseases 0.000 title claims abstract description 43
- 230000007882 cirrhosis Effects 0.000 title claims abstract description 43
- 238000009098 adjuvant therapy Methods 0.000 title claims abstract description 39
- 208000002672 hepatitis B Diseases 0.000 title claims abstract description 32
- 235000013311 vegetables Nutrition 0.000 title claims abstract description 28
- 235000013399 edible fruits Nutrition 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 230000001447 compensatory effect Effects 0.000 title description 9
- 235000020235 chia seed Nutrition 0.000 claims abstract description 25
- 244000157072 Hylocereus undatus Species 0.000 claims abstract description 23
- 235000004611 garlic Nutrition 0.000 claims abstract description 23
- 235000018290 Musa x paradisiaca Nutrition 0.000 claims abstract description 20
- 235000013305 food Nutrition 0.000 claims abstract description 20
- 244000017020 Ipomoea batatas Species 0.000 claims abstract description 19
- 235000002678 Ipomoea batatas Nutrition 0.000 claims abstract description 19
- 235000003228 Lactuca sativa Nutrition 0.000 claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 13
- 235000010837 Echinocereus enneacanthus subsp brevispinus Nutrition 0.000 claims abstract description 9
- 235000006850 Echinocereus enneacanthus var dubius Nutrition 0.000 claims abstract description 9
- 240000008415 Lactuca sativa Species 0.000 claims abstract description 7
- 235000001808 Ceanothus spinosus Nutrition 0.000 claims abstract description 6
- 241001264786 Ceanothus spinosus Species 0.000 claims abstract description 6
- 240000008790 Musa x paradisiaca Species 0.000 claims abstract 6
- 240000002234 Allium sativum Species 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 235000018481 Hylocereus undatus Nutrition 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 10
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 9
- 239000011707 mineral Substances 0.000 claims description 9
- 241000234282 Allium Species 0.000 claims description 8
- 235000002732 Allium cepa var. cepa Nutrition 0.000 claims description 8
- 235000021537 Beetroot Nutrition 0.000 claims description 8
- 235000004936 Bromus mango Nutrition 0.000 claims description 8
- 240000007228 Mangifera indica Species 0.000 claims description 8
- 235000014826 Mangifera indica Nutrition 0.000 claims description 8
- 235000009184 Spondias indica Nutrition 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 235000012905 Brassica oleracea var viridis Nutrition 0.000 claims description 7
- 235000004347 Perilla Nutrition 0.000 claims description 7
- 244000124853 Perilla frutescens Species 0.000 claims description 7
- 235000009337 Spinacia oleracea Nutrition 0.000 claims description 7
- 244000300264 Spinacia oleracea Species 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 235000000832 Ayote Nutrition 0.000 claims description 6
- 244000025254 Cannabis sativa Species 0.000 claims description 6
- 235000009854 Cucurbita moschata Nutrition 0.000 claims description 6
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 235000004426 flaxseed Nutrition 0.000 claims description 6
- 208000006454 hepatitis Diseases 0.000 claims description 6
- 235000015136 pumpkin Nutrition 0.000 claims description 6
- 240000007124 Brassica oleracea Species 0.000 claims description 5
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 claims description 5
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 claims description 5
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 claims description 5
- 240000004244 Cucurbita moschata Species 0.000 claims description 5
- 240000006240 Linum usitatissimum Species 0.000 claims description 5
- 235000004431 Linum usitatissimum Nutrition 0.000 claims description 5
- 235000009120 camo Nutrition 0.000 claims description 5
- 235000005607 chanvre indien Nutrition 0.000 claims description 5
- 239000011487 hemp Substances 0.000 claims description 5
- 231100000283 hepatitis Toxicity 0.000 claims description 5
- 244000000231 Sesamum indicum Species 0.000 claims description 4
- 235000003434 Sesamum indicum Nutrition 0.000 claims description 4
- 244000061456 Solanum tuberosum Species 0.000 claims description 4
- 235000002595 Solanum tuberosum Nutrition 0.000 claims description 4
- 240000004201 Lactuca sativa var. crispa Species 0.000 claims description 3
- 244000223014 Syzygium aromaticum Species 0.000 claims description 3
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000010025 steaming Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 238000003860 storage Methods 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 3
- 229960000590 celecoxib Drugs 0.000 claims 3
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 claims 1
- LUSZGTFNYDARNI-UHFFFAOYSA-N Sesamol Natural products OC1=CC=C2OCOC2=C1 LUSZGTFNYDARNI-UHFFFAOYSA-N 0.000 claims 1
- 238000002791 soaking Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 18
- 235000015097 nutrients Nutrition 0.000 abstract description 9
- 239000000126 substance Substances 0.000 abstract description 7
- 238000002560 therapeutic procedure Methods 0.000 abstract description 7
- 241000700605 Viruses Species 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 6
- 210000005229 liver cell Anatomy 0.000 abstract description 5
- 206010061218 Inflammation Diseases 0.000 abstract description 4
- 230000004054 inflammatory process Effects 0.000 abstract description 4
- 208000032544 Cicatrix Diseases 0.000 abstract description 3
- 235000005911 diet Nutrition 0.000 abstract description 3
- 230000002440 hepatic effect Effects 0.000 abstract description 3
- 231100000241 scar Toxicity 0.000 abstract description 3
- 230000037387 scars Effects 0.000 abstract description 3
- 230000000378 dietary effect Effects 0.000 abstract description 2
- 230000036039 immunity Effects 0.000 abstract description 2
- 240000009239 Tulbaghia violacea Species 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 description 26
- 238000011282 treatment Methods 0.000 description 18
- 240000005561 Musa balbisiana Species 0.000 description 16
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 14
- 241000208822 Lactuca Species 0.000 description 12
- 230000000840 anti-viral effect Effects 0.000 description 10
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 235000015203 fruit juice Nutrition 0.000 description 8
- 235000010755 mineral Nutrition 0.000 description 8
- 235000015192 vegetable juice Nutrition 0.000 description 8
- 229910052742 iron Inorganic materials 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 241000220225 Malus Species 0.000 description 6
- 229910052700 potassium Inorganic materials 0.000 description 6
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 206010016256 fatigue Diseases 0.000 description 5
- 239000002777 nucleoside Substances 0.000 description 5
- 150000003833 nucleoside derivatives Chemical class 0.000 description 5
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 235000007686 potassium Nutrition 0.000 description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 4
- 206010041660 Splenomegaly Diseases 0.000 description 4
- 235000021152 breakfast Nutrition 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229960000980 entecavir Drugs 0.000 description 4
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 235000013734 beta-carotene Nutrition 0.000 description 3
- 239000011648 beta-carotene Substances 0.000 description 3
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 3
- 229960002747 betacarotene Drugs 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 235000012661 lycopene Nutrition 0.000 description 3
- 229960004999 lycopene Drugs 0.000 description 3
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 3
- 239000001751 lycopene Substances 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229960003712 propranolol Drugs 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 3
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 description 2
- 244000064816 Brassica oleracea var. acephala Species 0.000 description 2
- 241000218236 Cannabis Species 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 108010076986 Phytochelatins Proteins 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010046996 Varicose vein Diseases 0.000 description 2
- 229930003448 Vitamin K Natural products 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 description 2
- 235000010081 allicin Nutrition 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940111133 antiinflammatory and antirheumatic drug oxicams Drugs 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 235000021015 bananas Nutrition 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 235000019804 chlorophyll Nutrition 0.000 description 2
- 229930002875 chlorophyll Natural products 0.000 description 2
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000012055 fruits and vegetables Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000004383 glucosinolate group Chemical group 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 229960003560 tenofovir alafenamide fumarate Drugs 0.000 description 2
- SVUJNSGGPUCLQZ-FQQAACOVSA-N tenofovir alafenamide fumarate Chemical compound OC(=O)\C=C\C(O)=O.O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1.O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1 SVUJNSGGPUCLQZ-FQQAACOVSA-N 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 208000027185 varicose disease Diseases 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 235000019168 vitamin K Nutrition 0.000 description 2
- 239000011712 vitamin K Substances 0.000 description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Chemical group OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 235000008697 Cannabis sativa Nutrition 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000219122 Cucurbita Species 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010073306 Exposure to radiation Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 206010018276 Gingival bleeding Diseases 0.000 description 1
- 206010054787 Haemorrhoidal haemorrhage Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 206010024652 Liver abscess Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 235000012377 Salvia columbariae var. columbariae Nutrition 0.000 description 1
- 240000005481 Salvia hispanica Species 0.000 description 1
- 235000001498 Salvia hispanica Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010041519 Spider naevus Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Chemical group OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Chemical group 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000023505 abnormal feces Diseases 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical group OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000000656 anti-yeast Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000015191 beet juice Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000014167 chia Nutrition 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 229940106705 chlorophyll Drugs 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical group C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 201000011200 hepatorenal syndrome Diseases 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 235000002908 manganese Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 235000020166 milkshake Nutrition 0.000 description 1
- 208000011309 nasal bleeding Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 239000001053 orange pigment Substances 0.000 description 1
- 125000001741 organic sulfur group Chemical group 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000001054 red pigment Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229960005311 telbivudine Drugs 0.000 description 1
- IQFYYKKMVGJFEH-CSMHCCOUSA-N telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229960004556 tenofovir Drugs 0.000 description 1
- 229960001355 tenofovir disoproxil Drugs 0.000 description 1
- JFVZFKDSXNQEJW-CQSZACIVSA-N tenofovir disoproxil Chemical compound N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N JFVZFKDSXNQEJW-CQSZACIVSA-N 0.000 description 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Chemical group 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Chemical group 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- -1 vitamin C Natural products 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/09—Mashed or comminuted products, e.g. pulp, purée, sauce, or products made therefrom, e.g. snacks
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
- A23L19/105—Sweet potatoes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
- A23L19/12—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops of potatoes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L25/00—Food consisting mainly of nutmeat or seeds; Preparation or treatment thereof
- A23L25/30—Mashed or comminuted products, e.g. pulp, pastes, meal, powders; Products made therefrom, e.g. blocks, flakes, snacks; Liquid or semi-liquid products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/33—Cactaceae (Cactus family), e.g. pricklypear or Cereus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种用于辅助治疗代偿期乙肝后肝硬化的蔬果昔及制作方法。该蔬果昔选用药食同源食物:红心火龙果、生菜、香蕉、奇亚籽、红薯和大蒜等作为原料,40℃以下低温破壁机搅拌而成。本发明的蔬果昔具有抗病毒、抗炎、修复肝组织疤痕、促进肝脏新细胞生成、提供高效营养物质以及提高机体免疫力等作用,且制作过程简单,原料经济、易得,是一种健康、无任何副作用、能辅助治疗代偿期乙肝后肝硬化的食疗配方,一般患者和家庭都能适用,具有极强的推广性。
Description
技术领域
本领域属于药食同源领域,具体是涉及一种辅助治疗代偿期乙肝肝硬化的蔬果昔及其制作方法和应用。
背景技术
慢性乙型肝炎是我国的常见病和多发病,病情进展至肝炎后肝硬化是慢性肝炎患者死亡的主要原因。目前,长期抗病毒是治疗乙肝肝硬化的主要治疗原则,根据乙肝肝硬化的不同发展阶段选择不同的抗病毒药物。肝硬化患者处于代偿期,抗病毒治疗的药物可选择干扰素和核苷(酸)类似物,选择干扰素一定要注意干扰素治疗的不良反应和禁忌证;处于失代偿期,抗病毒治疗的药物只能选择核苷(酸)类似物,在目前的5类核苷(酸)类似物中,原则上是选择强效低耐药药物替诺福韦酯或恩替卡韦单药治疗,不主张序贯治疗,治疗过程中还需要注意核苷(酸)类似物的不良反应。如果选择了替比夫定、拉米夫定,则需进行优化治疗。但是,很多临床效果表明,无论选择哪种抗病毒药物治疗,只要没有达到完全治愈,抗病毒治疗会在一定程度上改善患者的已有不良症状,如食欲减退、腹胀、乏力、牙龈鼻腔出血、口角发炎、蜘蛛痣、肝掌、脾肿大、皮肤瘙痒、食管胃底静脉曲张、肝肾综合症、肝性脑病等,同时也带来了不可抗拒的副作用。如被认为抗病毒效果最好、安全性最强的核苷(酸)类药物TAF (富马酸替诺福韦艾拉酚胺,tenofovir alafenamide fumarate)的最常见副作用为头疼、胃痛、疲倦、咳嗽、恶心和背痛,长期使用还会带来肾功能衰竭、乳酸性酸中毒、乙型肝炎感染恶化、肝中毒等其他副作用。
中医药被认为对代偿期乙肝肝硬化的治疗有独特的疗效,可以弥补西医治疗用药上的匮乏,如中国发明专利申请公布号CN 103494907A公开了一种治疗代偿期肝硬化的软肝丸,中国发明专利申请公布号CN11057575521A公开了一种用于治疗慢性乙型肝炎及乙型肝炎相关性代偿期肝硬化的中药组合物。但乙肝后肝硬化患者需要长期服用中药,由于主客观原因,也导致了中药治疗也会带来一定的副作用。如有不少媒体报道过中药治疗肝硬化会导致肝肾中毒等副作用的案例。
俗话说“是药三分毒”,无论是单纯地西药治疗还是单纯地中药治疗,抑或是中西医结合治疗,都会对乙肝后肝硬化患者带来不容忽视的副作用,影响治疗效果,拉长治疗时间,久而久之危及患者的生命。目前对大多数医院医生和患者而言,乙肝后肝硬化治疗是一个漫长而又看不到希望完全治愈的过程,其结局差不多是注定的,这种绝望使患者承受肉体、经济和精神上的巨大压力,也给其整个家庭的生活蒙上了一层阴影。因此,探索一种经济、健康、无副作用、提高代偿期乙肝后肝硬化治疗效果的辅助食疗配方是众多医务工作者、研究者和患者家庭等相关人员面临的一个重要、急需解决问题。
发明内容
针对上述情况,为解决现有技术之缺陷,本发明提供一种辅助治疗代偿期乙肝后肝硬化的经济、健康和无副作用的食疗蔬果昔、制作方法及应用,从而在较短时间内对中西医治疗代偿期乙肝后肝硬化患者达到更理想的效果。
为实现上述技术目的,本发明的技术方案如下:
本发明提供了一种辅助治疗代偿期乙肝后肝硬化的蔬果昔,其特征在于所述蔬果昔由以下重量份的原料组成:红心火龙果4-14份,生菜4-18份,香蕉 3-9份,奇亚籽0.1-0.8份,红薯3-7份,大蒜0.05-0.15份。
优选的,所述蔬果昔由以下重量份的原料组成:红色火龙果8份,生菜14 份,香蕉6份,奇亚籽0.5份,红薯5份,大蒜0.1份。
优选的,所述红色火龙果由甜菜根或苹果代替,所述生菜由生菠菜、羽衣甘蓝或芝麻菜中的一种代替。
优选的,所述红薯由土豆或南瓜代替,香蕉被无花果或芒果代替。
优选地,所述大蒜由洋葱代替,所述奇亚籽选择紫苏籽、火麻籽或亚麻籽中的一种。
本发明还提供了一种上述辅助治疗代偿期乙肝后肝硬化蔬果昔的制作方法,其特征在于将所有食材洗净,按以下具体步骤操作:
(1)将红薯蒸熟,冷却;大蒜头去皮掰成蒜瓣;
(2)将红心火龙果、香蕉切丁,生菜切成小段;
(3)将步骤(1)和(2)的食材与奇亚籽一起放入破壁机,根据需要加矿泉水或温热水,保持温度40℃以下,按蔬果昔档搅拌1-2分钟;
(4)将上述所制作的蔬果昔直接食用,或装瓶密封冰箱保存。。
优选的,所述步骤(1)中的所述红薯生切丁,所述大蒜由洋葱代替。
优选的,所述步骤(2)中的所述红色火龙果由甜菜根或苹果代替,所述香蕉被无花果或芒果代替,所述生菜由生菠菜、羽衣甘蓝或芝麻菜中的一种代替。
优选的,所述步骤(3)中所述奇亚籽经过冷水泡4-12小时。
优选的,所述步骤(3)中所述奇亚籽由紫苏籽、火麻籽或亚麻籽中的一种代替。
本发明提供的蔬果昔中,所用食材主要围绕抗病毒、抗炎、修复肝组织疤痕、促进肝脏新细胞生成、提供高效营养物质以及提高机体免疫力等方面,对辅助代偿期乙肝后肝硬化治疗有着非常重要的促进作用。
红色火龙果中的红色色素能帮助肝脏更快地生成细胞,让肝脏得以再生,减缓和阻止肝脏衰老。本技术方案可以用新鲜或者冰冻红心火龙果,也可用纯火龙果粉。
生菜性质甘凉,味微苦,含有人体必需的8种氨基酸,其奥米伽3、钙和铁含量也很高,含有丰富的维生素C、β-胡萝卜素、叶酸和维生素E和K,可以帮助平衡血糖、强化肌肉和骨骼、建立健康的免疫系统。生菜也富含多种人体必需的微量矿物质盐,支持肾上腺、甲状腺等内分泌腺,能刺激肠道蠕动,清除肝脏和淋巴系统中的病毒,净化血液并帮助血液的生成。
香蕉味甘,性寒,无毒。清热,润肠,解毒,养阴润燥,生津止渴。主治热病烦渴,便秘,痔血等病症。其中,香蕉中的果糖可以为肝脏提供快速燃料,舒缓肠道内壁以及附着在肠道上的神经,具有抗菌、抗酵母、抗真菌作用,提升肝脏吸收营养的能力。
红薯富含诸如β-胡萝卜素、番茄素、维生素C、E和D以及锰和铁等矿物质等。其中的植物螯合素(phytochelatins)在体内会能与重金属(诸如铅、汞、铜和镉)结合,并将其从体内排出;番茄红素(lycopene)和氨基酸的结合能防辐射;富含的钾通过去除体内多余的钠来帮助降低血压。
奇亚籽是蛋白质、维生素E、B复合物以及钙、镁、硼、锌、锶和铁等矿物质的丰富来源,也含有高纤维、蛋白质以及极高的抗氧化物,有助于舒缓和清洁结肠并吸收毒素、增强肠道蠕动,帮助预防诸如心脏病、癌症和中风等健康问题。
大蒜营养成分相当的丰富,具有很好的食疗以及药用价值。大蒜含有大量维生素和矿物质,包括维生素C、B-6以及硒、钙、铜和铁等矿物质,具有较强的抗菌、抗癌、抗病毒、抗寄生虫特性。其中的大蒜素能通过抑制肝细胞内的 HMG-CoA还原酶和阻止血管中的血小板凝块显著降低胆固醇和血压。
与现有技术相比,本发明取得的有益效果为:(1)蔬果昔以大自然中的原始整全食物水果、蔬菜为原料,食材方便易得、价格低廉;操作所需破壁机价格便宜,操流程简单、省时,几乎适应所有患者家庭使用,适用性强,极大地降低了患者家庭的经济压力。(2)蔬果昔的制作过程全程低温操作,营养得到充分保全,非常有效地发挥了各食材的特有功能,蔬果昔口感好,几乎适用于所有患者人群。(3)蔬果昔的辅助治疗效果较为显著,是一种健康、无任何副作用的辅助治疗代偿期乙肝后肝硬化的食疗配方,具有较强的推广价值。
具体实施方式
下面通过具体实施例对本发明进一步阐述,但并不限制本发明。
实施例1
本发明的辅助治疗代偿期乙肝后肝硬化蔬果昔由以下重量份的原料制作而成:红心火龙果4份,生菜4份,香蕉3份,奇亚籽0.1份,红薯3份,大蒜 0.05份。其中,红色火龙果可由甜菜根或苹果代替;生菜可由生菠菜、羽衣甘蓝或芝麻菜中的一种代替;香蕉可以用无花果或芒果代替;红薯由土豆或南瓜代替;大蒜由洋葱代替;奇亚籽选择使用紫苏籽、火麻籽或亚麻籽中的一种。
甜菜根富含硝酸盐,经常饮用甜菜头汁,可以降血压、缓解疲劳、增强耐力;甜菜碱和植物营养素可以对抗及预防炎症和癌症;富含铁易人体吸收可以预防贫血;富含大量的膳食纤维可以缓解便秘,帮助调理肠胃排出毒素。
苹果提供活水来支持肝脏的水和能力,帮助肝脏储存水分,在脱水或肮脏血液综合症情况下,得以释放水分进入血液。苹果中营养成分可溶性大,易被人体吸收,含有铜、碘、锰、锌、钾等元素,具有降低胆固醇、宁神安眠、缓解疲劳等功效。
生菠菜是富含矿物质、蛋白质、铁、β-胡萝卜素和叶绿素,含有增强免疫系统以及保持骨骼和肌肉强壮必需的营养元素。生菠菜能够去除肝脏内的大量病毒产生的啫喱状废弃物,从而净化血液;同时也能帮助去除体内的其他各种毒性,为神经系统提供高度可吸收的微量营养素。
羽衣甘蓝是一种营养非常丰富的绿叶蔬菜,含有丰富的奥米伽3脂肪酸、叶绿素、氨基酸、维生素A、C、E、K和B族复合物和各种矿物质诸如铁、镁、铜和钾,类胡萝卜素,类黄酮,硫代葡萄糖苷,有机硫等,具有较好的疗愈和恢复人体活力的特性。其中,所含硫代葡萄糖苷和有机硫具有抗病毒和抗炎特性。
芝麻菜可以减少结节、肿瘤和囊肿,能帮助从肝脏中排出过去的化学药品残留,帮助肝脏温和地排毒。
土豆富含的钾和丰富的维生素B6,有助于新肝细胞的形成;所含赖氨酸能够治疗癌症、肝脏疾病、各种炎症、自身免疫缺陷疾病(诸如类风湿性关节炎等)以及杀死引起慢性疾病的病毒,具有抗病毒、抗细菌、抗真菌特效;所富含葡萄糖是肝脏保持强健所需的关键物质。
南瓜富含肝脏可以轻易储存的营养物质,所含丰富的胡萝卜素能保护肝脏细胞免受伤害。南瓜中的葡萄糖能稳定肝脏,维持整个身体的血糖水平稳定。而且南瓜很容易消化,能够缓解体内酸中毒(身体毒性),改善胃、脾、肝脏和血液问题,并帮助对抗各种流感。
无花果中含有大量的钾、苹果酸、纤维素等营养成分,能够缓解高血压,改善微循环,增强消化功能,促进消化道吸收,增加饱腹感,清除体内自由基,排除身体的各种病原体和毒素。
芒果能够冷却高毒性、过热的肝脏,并舒缓和镇定肝脏,防止肝脏痉挛;可以帮助肝脏的免疫系统破坏造成肝脏脓肿的细菌囊袋,帮助防止肝脏老化和细胞死亡,同时提升胆汁产量;其中黄橙色的色素为肝小叶提供养分,并增强肝细胞和库普弗细胞的功能,使它们能够完成所要做的工作。
洋葱因含硫包括蒜素及他有机硫化物使其成为的天然抗生素。洋葱可以帮助身体摆脱接触到的辐射物、驱除病毒,排除DDT、有毒重金属、其他杀虫剂与除草剂等,在舒缓关节疼痛、退化以及修复肌腱、结缔组织等方面有绝佳效果。洋葱非常有助于疗愈慢性阻塞性肺病、高血压、肝脏疾病、脂肪肝等疾病和身体疼痛、口疮、缺铁、肌腱发炎、疤痕、脾脏肿大等多种症状。
紫苏籽、火麻仁或亚麻籽都是健康ω-3(奥米茄3)脂肪酸的丰富来源。ω -3(奥米茄3)脂肪酸属多元非饱和脂肪酸,是人体细胞结构中最重要的成份之一,也是细胞膜运作正常必需物质,又称必需脂肪酸。紫苏籽、火麻仁或亚麻籽均具有极强的抗炎作用,增加吸收ω-3(奥米茄3)脂肪酸对疗愈很多种慢性病都有帮助。
实施例2
本发明的辅助治疗代偿期乙肝后肝硬化蔬果昔由以下重量份的原料制作而成:红心火龙果14份,生菜18份,香蕉9份,奇亚籽0.8份,红薯7份,大蒜0.15份。
实施例3
本发明的辅助治疗代偿期乙肝后肝硬化蔬果昔由以下重量份的原料制作而成:红心火龙果9份,生菜11份,香蕉6份,奇亚籽0.45份,红薯5份,大蒜0.1份。
实施例4
本发明的辅助治疗代偿期乙肝后肝硬化蔬果昔由以下重量份的原料制作而成:红色火龙果8份,生菜14份,香蕉6份,奇亚籽0.5份,红薯5份,大蒜 0.1份。
实施例5
本发明还提供一种以上所述辅助治疗代偿期乙肝后肝硬化蔬果昔的制作方法,按重量组成称取原料并洗净、沥水、去皮,具体按以下步骤操作:(1)将红薯蒸熟,冷却,大蒜头去皮掰成蒜瓣;(2)将红心火龙果、香蕉切丁,生菜切成小段;(3)将步骤(1)和步骤(2)的食材与奇亚籽一起放入破壁机,根据需要加矿泉水或温热水,保持温度40℃以下,按蔬果昔档搅拌1-2分钟;(4) 将上述所制作的蔬果昔直接食用,或装瓶密封,冰箱冷藏或冷冻保存。
实施例6
制作辅助治疗代偿期乙肝后肝硬化蔬果昔时,步骤(1)中所用的红薯不需要蒸熟,直接生切丁,所用大蒜用洋葱代替,其他步骤同实施例5。
实施例7
制作辅助治疗代偿期乙肝后肝硬化蔬果昔时,步骤(3)中的红色火龙果和香蕉分别由甜菜根和无花果代替,生菜由生菠菜代替,其他步骤同实施例5。
实施例8
制作辅助治疗代偿期乙肝后肝硬化蔬果昔时,步骤(3)中的红色火龙果和香蕉分别由苹果和芒果代替,生菜用由羽衣甘蓝代替,其他步骤同实施例5。
实施例9
制作辅助治疗代偿期乙肝后肝硬化蔬果昔时,步骤(3)中的红色火龙果和香蕉分别用甜菜根和芒果代替,生菜用芝麻菜代替,其他步骤同实施例5。
实施例10
制作辅助治疗代偿期乙肝后肝硬化蔬果昔时,步骤(3)中奇亚籽经过冷水泡4小时后再加入破壁机,其他步骤同实施例5。
实施例11
制作辅助治疗代偿期乙肝后肝硬化蔬果昔时,步骤(3)中奇亚籽经过冷水泡12小时后再加入破壁机,其他步骤同实施例5。
实施例12
制作辅助治疗代偿期乙肝后肝硬化蔬果昔时,步骤(3)中奇亚籽经过冷水泡8小时后再加入破壁机,其他步骤同实施例5。
实施例13
制作辅助治疗代偿期乙肝后肝硬化蔬果昔时,步骤(3)中奇亚籽用紫苏籽代替,其他步骤同实施例5。
实施例14
制作辅助治疗代偿期乙肝后肝硬化蔬果昔时,步骤(3)中奇亚籽用火麻籽代替,其他步骤同实施例5。
实施例15
制作辅助治疗代偿期乙肝后肝硬化蔬果昔时,步骤(3)中的奇亚籽用亚麻籽代替,其他步骤同实施例5。
将实施例1食材配方所制作的蔬果昔用于辅助治疗代偿期乙肝后肝硬化患者的实例介绍。
患者甲,女,48岁,在医院工作。患者自2015年10月查出早期肝硬化始开始服用恩替卡韦和心得安,如此服药到2017年5月,病情出现恶化症状,如便秘、尿频、易疲劳、低热、失眠、贫血、脾大、皮肤瘙痒、心颤、肝部肿胀、双腿浮肿、肝肾功能不正常等,无法正常工作,于是辞职到处寻医问药,但病情一直未见好转,甚至进一步恶化向。2019年3月,患者接触到该纯食物性蔬果昔进行辅助治疗。使用方法为:每天保留服用恩替卡韦和心得安的常规治疗外,早餐空腹食用该蔬果昔至饱感,早、中饭之间如果感到饥饿喝蔬果昔或吃新鲜蔬菜、水果,中餐之前不摄入脂肪,中、晚餐尽量饮食清淡。经过近6个月的食疗,患者身上的不良症状几乎完全消失,肝肾功能基本恢复正常,脾脏明显缩小,精力较为旺盛。于2021年3月开始恢复正常工作(不上夜班),至今没任何不适,且经医院检查,各项指标接近正常。
患者乙,男,52岁,无腹水,2019年7月胃底静脉曲张大出血。此后,坚持抗病毒和中药调理,但效果还是不能令人满意。患者开始接触到该辅助治疗方法时症状如下:全身浮肿、大小便异常、胃口差、皮肤发黄、睡眠障碍、月经不调、双腿无力、脾脏肿大、肝掌、身体虚弱等。于2021年4月,在保持替诺福韦抗病毒治疗和中药治疗的同时,采用该蔬果昔辅助治疗。7个月后各项检查指标明显改善,所有不良症状几乎消失或接近消失,并于2021年12月停用中药至今没有反弹,且身体各种感觉和检查指标越来越好。
以上只是列举了利用本发明蔬果昔辅助治疗代偿期乙肝后肝硬化2个患者的例子,其实此类例子很多,在此不一一赘述。
本发明提供的用于辅助治疗代偿期乙肝后肝硬化的蔬果昔采用大自然全整食物为原料,是兼有药食同源的原理组合,采用原始食材低温破壁机打成奶昔状,制作过程简单,所得蔬果昔口感好,各种营养物质完好保留,营养价值高,辅助治疗短时间内症状改善效果显著且不易复发,没任何副作用,价美物廉、经济实用,一般患者和家庭都能适用,具有较强的推广价值。
最后所应说明的是,以上具体实施方式仅用以说明本发明的技术方案而非限制,尽管参照较佳实施例对本发明进行了详细说明,本领域的普通技术人员应当理解,可以对本发明的技术方案进行修改或者等同替换,而不脱离本发明技术方案的精神和范围,其均应涵盖在本发明的权利要求范围当中。
Claims (10)
1.一种用于辅助治疗代偿期乙肝后肝硬化的蔬果昔,其特征在于由以下重量份的原料制作而成:红心火龙果4-14份,生菜4-18份,香蕉3-9份,奇亚籽0.1-0.8份,红薯3-7份,大蒜0.05-0.15份。
2.根据权利要求1所述的用于辅助治疗代偿期乙肝后肝硬化的蔬果昔,其特征在于由以下重量份的原料制作而成:红色火龙果8份,生菜14份,香蕉6份,奇亚籽0.5份,红薯5份,大蒜0.1份。
3.根据权利要求1所述的用于辅助治疗代偿期乙肝后肝硬化的蔬果昔,其特征在于:所述红色火龙果由甜菜根或苹果代替,所述生菜由生菠菜、羽衣甘蓝或芝麻菜中的一种代替。
4.根据权利要求1所述的用于辅助治疗代偿期乙肝后肝硬化的蔬果昔,其特征在于:所述红薯由土豆或南瓜代替,香蕉被无花果或芒果代替。
5.根据权利要求1所述的用于辅助治疗代偿期乙肝后肝硬化的蔬果昔,其特征在于:所述大蒜由洋葱代替,所述奇亚籽选择紫苏籽、火麻籽或亚麻籽中的一种。
6.一种制备权利要求1所述用于辅助治疗代偿期乙肝后肝硬化组合物蔬果昔的制作方法,其特征在于按重量组成称取食材并洗净、去皮,具体按以下步骤操作:
(1)将红薯蒸熟,冷却;大蒜头去皮掰成蒜瓣;
(2)将红心火龙果、香蕉切丁,生菜切成小段;
(3)将步骤(1)和(2)的食材与奇亚籽一起放入破壁机,根据需要加矿泉水或温热水,保持温度40℃以下,按蔬果昔档搅拌1-2分钟;
(4)将上述所制作的蔬果昔直接食用,或装瓶密封冰箱保存。
7.根据权利要求6所述用于辅助治疗代偿期乙肝后肝硬化组合物蔬果昔的制作方法,其特征在于:所述步骤(1)中所述红薯生切丁,所述大蒜由洋葱代替。
8.根据权利要求6所述用于辅助治疗代偿期乙肝后肝硬化组合物蔬果昔的制作方法,其特征在于,所述步骤(3)中的红色火龙果由甜菜根或苹果代替,所述香蕉被无花果或芒果代替,所述生菜由生菠菜、羽衣甘蓝或芝麻菜中的一种代替。
9.根据权利要求6所用于述辅助治疗代偿期乙肝后肝硬化组合物蔬果昔的制作方法,其特征在于:所述步骤(3)中所述奇亚籽经过冷水泡4-12小时。
10.根据权利要求6所述用于辅助治疗代偿期乙肝后肝硬化组合物蔬果昔的制作方法,其特征在于:所述用于步骤(3)中所述奇亚籽由紫苏籽、火麻籽或亚麻籽中的一种代替。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210622759.8A CN115088822A (zh) | 2022-06-02 | 2022-06-02 | 一种用于辅助治疗代偿期乙肝后肝硬化的蔬果昔及制作方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210622759.8A CN115088822A (zh) | 2022-06-02 | 2022-06-02 | 一种用于辅助治疗代偿期乙肝后肝硬化的蔬果昔及制作方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115088822A true CN115088822A (zh) | 2022-09-23 |
Family
ID=83288276
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210622759.8A Pending CN115088822A (zh) | 2022-06-02 | 2022-06-02 | 一种用于辅助治疗代偿期乙肝后肝硬化的蔬果昔及制作方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115088822A (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102687882A (zh) * | 2012-06-09 | 2012-09-26 | 东莞市照燕生物科技有限公司 | 一种肝脏保健果蔬汁配方及其制备工艺 |
CN104840883A (zh) * | 2015-05-15 | 2015-08-19 | 朱黎明 | 治疗肝硬化失代偿期的中药 |
CN105663900A (zh) * | 2016-03-08 | 2016-06-15 | 河南中医学院第一附属医院 | 一种用于改善肝硬化营养状态的药膳 |
CN109999169A (zh) * | 2019-04-19 | 2019-07-12 | 洪宜超 | 一种用于治疗肝硬化的中药组合物 |
CN110236055A (zh) * | 2019-07-29 | 2019-09-17 | 卢珊玲 | 一种护肝的果蔬酵素饮料及其制备方法 |
CN111150826A (zh) * | 2020-02-17 | 2020-05-15 | 河南中医药大学 | 一种治疗代偿期乙肝后肝硬化的中药 |
-
2022
- 2022-06-02 CN CN202210622759.8A patent/CN115088822A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102687882A (zh) * | 2012-06-09 | 2012-09-26 | 东莞市照燕生物科技有限公司 | 一种肝脏保健果蔬汁配方及其制备工艺 |
CN104840883A (zh) * | 2015-05-15 | 2015-08-19 | 朱黎明 | 治疗肝硬化失代偿期的中药 |
CN105663900A (zh) * | 2016-03-08 | 2016-06-15 | 河南中医学院第一附属医院 | 一种用于改善肝硬化营养状态的药膳 |
CN109999169A (zh) * | 2019-04-19 | 2019-07-12 | 洪宜超 | 一种用于治疗肝硬化的中药组合物 |
CN110236055A (zh) * | 2019-07-29 | 2019-09-17 | 卢珊玲 | 一种护肝的果蔬酵素饮料及其制备方法 |
CN111150826A (zh) * | 2020-02-17 | 2020-05-15 | 河南中医药大学 | 一种治疗代偿期乙肝后肝硬化的中药 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103859518B (zh) | 一种预防心脑血管疾病的果蔬汁饮品及其制备方法 | |
CN103519171A (zh) | 一种仙人掌酵素的制备方法 | |
CN103610153A (zh) | 一种健脾养生汤及其制作方法 | |
CN102048225B (zh) | 一种具有改善生长发育功能的红枣保健饮料 | |
CN103610058A (zh) | 一种冬季滋补膏及加工工艺 | |
CN105124347A (zh) | 一种辣木降血糖组合物及其制备方法 | |
CN103610182A (zh) | 一种预防脂肪肝的天然饮料及生产工艺 | |
CN1315418C (zh) | 黑木耳燕麦螺旋藻即冲饮品及其制备方法 | |
CN100350860C (zh) | 混合浓缩果汁、制备方法及其应用 | |
CN101715989B (zh) | 一种营养鸡汤冻及其制做方法 | |
CN1904023A (zh) | 一种保健葡萄饮品 | |
CN104982740A (zh) | 舒缓犬骨关节的营养粮及制作方法 | |
CN100574786C (zh) | 一种甲鱼制剂的生产工艺 | |
CN1935030A (zh) | 药膳海参食品 | |
CN107279613A (zh) | 一种脑血栓食疗保健饮品 | |
CN115088822A (zh) | 一种用于辅助治疗代偿期乙肝后肝硬化的蔬果昔及制作方法 | |
CN104855960A (zh) | 创伤感染手术及其它应急状态非全营养配方食品 | |
CN101797049B (zh) | 营养八珍汤及其制备工艺 | |
CN103637308A (zh) | 一种具有排毒效果的果蔬饮料及其制作方法 | |
CN107549692A (zh) | 一种用于化疗患者术后恢复的海洋多肽特膳食品 | |
CN113812637A (zh) | 术前术后营养补充剂及应用 | |
CN103789147A (zh) | 一种山楂长生固本酒 | |
CN1714653A (zh) | 一种面包及其制备方法 | |
CN110013028A (zh) | 一种食疗养生保健产品 | |
CN103610068A (zh) | 一种降血脂海参口服液的制造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |